{"id":2420,"date":"2026-07-21T07:19:01","date_gmt":"2026-07-20T23:19:01","guid":{"rendered":"https:\/\/nichebeaty.com\/index.php\/2026\/07\/21\/fda-approves-new-drug-that-could-slow-breast-cancer-progression\/"},"modified":"2026-07-21T07:19:01","modified_gmt":"2026-07-20T23:19:01","slug":"fda-approves-new-drug-that-could-slow-breast-cancer-progression","status":"publish","type":"post","link":"https:\/\/nichebeaty.com\/index.php\/2026\/07\/21\/fda-approves-new-drug-that-could-slow-breast-cancer-progression\/","title":{"rendered":"FDA Approves New Drug That Could Slow Breast Cancer Progression"},"content":{"rendered":"<p><\/p>\n<div>\n<p class=\"text-md mb-6 leading-relaxed text-gray-500\">The U.S. Food and Drug Administration (FDA) has approved new targeted therapy for certain patients with advanced breast cancer whose disease has progressed despite hormone therapy. The approval gives breast cancer patients another option for one of the most common forms of advanced breast cancer.<\/p>\n<p class=\"text-md mb-6 leading-relaxed text-gray-500\">The treatment, called REVTORPYK (gedatolisib), from Celulicity,\u00a0is approved for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer whose tumors do not have a PIK3CA mutation. While those terms may sound technical, this subtype accounts for the majority of breast cancer diagnoses, and many patients eventually need additional treatment when hormone therapy is no longer effective.<\/p>\n<\/div>\n<div>\n<h2 id=\"impressive-trial-results\" class=\"font-canela mb-4 mt-8 text-2xl font-light leading-tight text-black md:text-3xl\"><strong class=\"font-semibold\">Impressive Trial Results<\/strong><\/h2>\n<p class=\"text-md mb-6 leading-relaxed text-gray-500\">The FDA&#8217;s decision was based on results from the phase 3 VIKTORIA-1 clinical trial. Patients who received the drug alongside the breast cancer drugs fulvestrant and palbociclib (Ibrance) stayed free from disease progression for a median of 9.3 months, compared with 2 months for patients who received fulvestrant alone. Overall, the combination reduced the risk of disease progression or death by 76 percent.<\/p>\n<h2 id=\"why-experts-are-encouraged\" class=\"font-canela mb-4 mt-8 text-2xl font-light leading-tight text-black md:text-3xl\"><strong class=\"font-semibold\">Why Experts Are Encouraged<\/strong><\/h2>\n<p class=\"text-md mb-6 leading-relaxed text-gray-500\">Seattle oncologist, Sara Hurvitz, MD, senior vice president of the Clinical Research Division at Fred Hutchinson Cancer Center and co-principal investigator of the VIKTORIA-1 trial, told\u00a0<em class=\"italic\">OncLive<\/em>\u00a0the approval addresses a significant unmet need for patients with this type of advanced breast cancer.<\/p>\n<p class=\"text-md mb-6 leading-relaxed text-gray-500\">&#8220;For patients with HR-positive\/HER2-negative locally advanced or metastatic breast cancer, there is an urgent need for new treatment options that can meaningfully increase the likelihood of survival without disease progression or death. With the approval of REVTORPYK, oncologists now have an effective new treatment option for these patients.&#8221;<\/p>\n<h2 id=\"what-patients-should-know\" class=\"font-canela mb-4 mt-8 text-2xl font-light leading-tight text-black md:text-3xl\"><strong class=\"font-semibold\">What Patients Should Know<\/strong><\/h2>\n<p class=\"text-md mb-6 leading-relaxed text-gray-500\">REVTORPYK is used in combination with existing breast cancer medications and works by targeting multiple pathways that cancer cells use to grow. Researchers believe that broader approach may help overcome treatment resistance that can develop over time.<\/p>\n<p class=\"text-md mb-6 leading-relaxed text-gray-500\">As with many cancer therapies, the treatment can cause side effects. The most common include mouth sores, nausea, rash, fatigue and elevated blood sugar. Patients taking the medication will be monitored throughout treatment to help manage these effects. Celcuity expects REVTORPYK to become commercially available later this year.<\/p>\n<p class=\"text-md mb-6 leading-relaxed text-gray-500\"><em class=\"italic\">Adapted in part from reporting by<\/em>\u00a0OncLive,\u00a0<em class=\"italic\">an MJH Life Sciences publication.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) has approve [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2421,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55],"tags":[],"_links":{"self":[{"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/posts\/2420"}],"collection":[{"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/comments?post=2420"}],"version-history":[{"count":0,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/posts\/2420\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/media\/2421"}],"wp:attachment":[{"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/media?parent=2420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/categories?post=2420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nichebeaty.com\/index.php\/wp-json\/wp\/v2\/tags?post=2420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}